Results 81 to 90 of about 1,457,629 (200)
Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Background
Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...John M. Burke, Ira Zackon, Yunfei Wang, Kathleen M. Aguilar, John Murphy, Brittani Wayne, Jennifer Prescott, Siyang Leng, Inkyu Kim, Diana Chirovsky, Enrico de Nigris +10 morewiley +1 more sourceZanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
Drug Design, Development and Therapy, 2021 Joanna M Rhodes,1 Anthony R Mato2 1CLL Research and Treatment Center, Northwell Health Cancer Institute, Barbara and Donald Zucker School of Medicine at Northwell/Hofstra, New Hyde Park, NY, USA; 2Chronic Lymphocytic Leukemia Program, Memorial Sloan ...Rhodes JM, Mato ARdoaj Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods
We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.Andrea Visentin, Enrica Antonia Martino, Alessandro Cellini, Francesco Angotzi, Annalisa Pitino, Andrea Duminuco, Ernesto Vigna, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Anna Maria Frustaci, Marcello Riva, Sara Pepe, Adalberto Ibatici, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Francesco Malaspina, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Fraticelli, Candida Vitale, Azzurra Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozella, Luigi Malandruccolo, Marzia Varettoni, Lucia Morello, Giuseppe Pietrantuono, Esmeralda Conte, Martina Cantelli, Roberta Murru, Daniele Caracciolo, Enrico Derenzini, Valentina Di Martina, Roberto Marasca, Maria Ilaria Del Principe, Amalia Figuera, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Nicola Amodio, Alessandro Allegra, Vittorio Del Fabro, Paolo Fiumara, Luca Scalise, Fabio Stagno, Giorgio Tona, Pellegrino Musto, Laura Caruso, Arcangelo Liso, Alessandra Tedeschi, Gianluca Gaidano, Francesca Romana Mauro, Giovanni Tripepi, Fortunato Morabito, Giuseppe Alberto Palumbo, Francesco Di Raimondo, Valter Gattei, Livio Trentin, Massimo Gentile +92 morewiley +1 more sourceA Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia
eJHaem, Volume 7, Issue 6, December 2026.ABSTRACT Introduction
BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.Steven M. Bair, John C. Byrd, Jonathan Gutman, Mitchell Phelps, Amy J. Johnson, Bita Fakhri, Kerry A. Rogers, Jennifer A. Woyach, Michael R. Grever, Manali Kamdar, Steven E. Coutre, Daniel A. Pollyea +11 morewiley +1 more sourceEarly Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX‐1/2 Phase 3 Studies
Clinical &Experimental Allergy, EarlyView.Gordon Sussman, Nadine Chapman‐Rothe, Tao Ding, Atsushi Fukunaga, Ana Maria Giménez‐Arnau, Michihiro Hide, Mark Lebwohl, Paula G. P. Machado, El‐Djouher Martzloff, Giselle Mosnaim, Christine‐Elke Ortmann, Petra Staubach, Hui Tang, Ansgar Weyergraf, Bin Yang, John Reed +15 morewiley +1 more sourceEconomic Burden of Chronic Lymphocytic Leukaemia in Australia
European Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.ABSTRACT Background
The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods
A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...Lan Gao, Dieu Nguyen, Victoria White, Patricia M. Livingston, Chan Y. Cheah +4 morewiley +1 more sourceShortened Obinutuzumab Infusion Is Safe and Reduces Chair Time in Frontline Treatment of Chronic Lymphocytic Leukemia: A Real‐World Study
Cancer Medicine, Volume 15, Issue 11, November 2026.In treatment‐naïve CLL, a shortened obinutuzumab infusion was as safe as standard infusion, did not increase infusion‐related reactions, and significantly reduced chair time, improving outpatient unit efficiency. ABSTRACT Background
Obinutuzumab‐based regimens are established frontline treatments for chronic lymphocytic leukemia (CLL), but infusion ...Dominika Écsiová, Eva Vejražková, Pavel Vodárek, Petra Rozsívalová, Lukáš Smolej, Pavel Žák, Martin Šimkovič +6 morewiley +1 more sourceAge, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Introduction
Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin +6 morewiley +1 more source